Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression

DOI: 10.1186/1750-9378-7-s1-o14

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text